AJCN EB Program 2010 Early Registration
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karamanlis, A.
Right arrow Articles by Rayner, C. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karamanlis, A.
Right arrow Articles by Rayner, C. K
Agricola
Right arrow Articles by Karamanlis, A.
Right arrow Articles by Rayner, C. K
American Journal of Clinical Nutrition, Vol. 86, No. 5, 1364-1368, November 2007
© 2007 American Society for Nutrition


ORIGINAL RESEARCH COMMUNICATION

Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects1,2,3

Angela Karamanlis, Reawika Chaikomin, Selena Doran, Max Bellon, F Dylan Bartholomeusz, Judith M Wishart, Karen L Jones, Michael Horowitz and Christopher K Rayner

1 From the University of Adelaide Discipline of Medicine (AK, RC, SD, JMW, KLJ, MH, and CKR), and the Department of Nuclear Medicine PET and Bone Densitometry (MB and FDB), Royal Adelaide Hospital, Adelaide, South Australia, Australia

2 Supported by a University of Adelaide Faculty of Health Sciences Research Establishment Grant (to CKR). RC's salary was provided by a scholarship from the Thai Government and the Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. KLJ's salary was funded jointly by Diabetes Australia and the National Health and Medical Research Council of Australia.

3 Address reprint requests to CK Rayner, Discipline of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia 5000. E-mail: chris.rayner{at}adelaide.edu.au.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Dietary interventions represent a promising therapeutic strategy to optimize postprandial glycemia. The addition of protein to oral glucose has been reported to improve the glycemic profile.

Objective: The aim of the current study was to evaluate the mechanisms by which protein supplementation lowers the blood glucose response to oral glucose.

Design: Nine healthy men were studied on 3 d each in a random order. Subjects consumed 300-mL drinks containing either 50 g glucose (Glucose), 30 g gelatin (Protein), or 50 g glucose with 30 g gelatin (Glucose + Protein) in water labeled with 150 mg [13C]acetate. Blood and breath samples were subsequently collected for 3 h to measure blood glucose and plasma insulin, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) concentrations and gastric half-emptying time, which was calculated from 13CO2 excretion.

Results: The blood glucose response was less after Glucose + Protein than after Glucose (P < 0.005); GIP was lower (P < 0.005), and there were no significant differences in plasma insulin or GLP-1. Protein alone stimulated insulin, GLP-1, and GIP (P < 0.05 for each) without elevating blood glucose. The gastric half-emptying time was greater after Glucose + Protein than after Glucose (P < 0.05) and tended to be greater for Glucose than for Protein (P = 0.06).

Conclusions: In healthy humans, the addition of protein to oral glucose lowers postprandial blood glucose concentrations acutely, predominantly by slowing gastric emptying, although protein also stimulates incretin hormones and non-glucose-dependent insulin release.

Key Words: Glucose-dependent insulinotropic polypeptide • glucagon-like peptide 1 • breath test


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Glycemic control is a major determinant of the development and progression of the complications associated with diabetes (1-3), and recent studies have highlighted the particular importance of postprandial hyperglycemia (4, 5). High-protein diets are reported to decrease both postprandial blood glucose and glycated hemoglobin in type 2 diabetes (6), but the mechanisms responsible for these effects are poorly defined.

The capacity of protein to enhance insulin secretion has been recognized for many years. Gannon et al (7) reported that the addition of 25 g protein (from sources such as meat, fish, or gelatin) to a 50-g oral glucose load reduced the subsequent blood glucose response in type 2 diabetic patients (by {approx}30% with gelatin), whereas it increased plasma insulin (by {approx}2.5 times with gelatin) when compared with glucose alone.

It is now established that the rate of gastric emptying is a major determinant of postprandial glycemia, so that even modest changes may have a substantial effect on the magnitude and timing of postprandial increases in blood glucose and insulin (8, 9). Gastric emptying is normally regulated at a relatively constant rate of 2–3 kcal/min, predominantly by feedback arising from the small intestine (10, 11). The addition of energy in the form of protein to an oral glucose load would be expected, therefore, to slow gastric emptying of glucose and thereby reduce the glycemic response. In this circumstance, it may be expected that there would be a reduction, rather than an increase, in the plasma insulin response. Previous studies that evaluated the effects of protein supplementation on oral glucose tolerance (7, 12, 13) did not measure the rate of gastric emptying.

Oral glucose stimulates insulin secretion to a much greater degree than does an equivalent intravenous glucose load (14). This "incretin effect" is mediated by the small intestinal peptides glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both carbohydrate and fat are potent stimuli for GLP-1 and GIP secretions(15), but the response to protein is more variable; amino acids (16-18) and casein hydrolysates (19) tend to stimulate GIP and GLP-1 more potently than do intact proteins, at least in healthy humans (15, 20). Strategies to enhance the incretin response are of particular interest in the management of patients with type 2 diabetes, in whom both the secretion of GLP-1 (21) and the ß cell response to GIP (22) appear to be impaired. We have now examined the potential contributions of gastric emptying, incretin peptides, and insulin in mediating the reduction in the glycemic response to oral glucose by the addition of protein, in healthy humans.


    SUBJECTS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Subjects
Nine healthy men [median age: 24 y (range: 19–35 y); median body mass index (in kg/m2): 24.2 (range: 21.6–27.5)] were studied. In each subject, measurements were performed on 3 d after an overnight fast, and each measurement was separated by ≥3 d.

Each subject gave written informed consent in accordance with the guidelines of the Declaration of Helsinki. The protocol was approved by the Research Ethics Committee of the Royal Adelaide Hospital.

Protocol
The order of the studies was randomized and single-blinded. An intravenous cannula was placed in a forearm vein 30 min before each study to allow repeated blood samples to be drawn.

On each day, a 300-mL drink was consumed, which contained 50 g glucose ("Glucose" drink; 200 kcal), 30 g powdered gelatin (incorporating 25 g protein; Davis Gelatin; Gelita NZ Ltd, Christchurch, New Zealand; "Protein" drink; 100 kcal), or both glucose and gelatin ("Glucose + Protein" drink; 300 kcal), dissolved in water. Each drink contained 150 mg [13C]acetate and nonnutritive fruit flavoring, was served at {approx}37 °C, and was consumed within 3 min.

Blood samples were collected at –5, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for measurements of blood glucose and plasma insulin, GLP-1, and GIP concentrations. To calculate the rate of gastric emptying, breath samples were obtained at 5-min intervals from 0 to 60 min and then at 15-min intervals from 60 to 180 min.

Measurements
Blood glucose, plasma insulin, GLP-1, and GIP concentrations
Blood samples for the determinations of plasma insulin, GLP-1, and GIP were collected in ice-chilled tubes containing EDTA and 400 kIU aprotonin (Trasylol; Bayer Australia Ltd, Pymble, Australia) per liter of blood. Plasma was separated by centrifugation and stored at –70 °C for subsequent analysis. Blood glucose concentrations were determined immediately by using a portable glucometer (Medisense Precision QID; Abbott Laboratories, Bedford, MA). The accuracy of this method was confirmed by our laboratory with the use of the hexokinase technique (8). Plasma insulin was measured by enzyme-linked immunosorbent assay (Diagnostics Systems Laboratories Inc, Webster, TX); the intraassay CV was 2.6%, and the interassay CV was 6.2% (23). Plasma GLP-1 concentrations were measured by radioimmunoassay; the intraassay CV was 17%, and the interassay CV was 18% (24). Plasma GIP was also measured by radioimmunoassay; intra- and interassay CVs were both 15% (24).

Gastric emptying
13CO2 enrichment in the breath samples was measured by mass spectroscopy (ABCA 20–20 mass spectrometer; Europa Scientific, Crewe, United Kingdom) to determine the percentage 13CO2 recovery per hour and the cumulative percentage 13CO2 recovery over 3 h (25). The method of Ghoos et al (26) was applied to calculate the gastric half-emptying time and gastric emptying coefficient. Breath tests that use the [13C]acetate label were validated against the gold standard of scintigraphy for the measurement of liquid gastric emptying (27).

Statistical analyses
Data were evaluated by use of analysis of variance for comparisons of peak blood glucose concentrations, gastric half-emptying time, and gastric emptying coefficient. Repeated-measures analysis of variance was used to compare blood glucose and plasma peptide data between 0 and 180 min, with post hoc comparisons in the event of a treatment x time interaction. The difference in the blood glucose increment at 15 min after Glucose + Protein and Glucose was calculated, as was the difference in gastric half-emptying time after these drinks, and the correlation between these variables was examined. Analyses were performed with the use of STATVIEW 5 software (SAS Institute, Cary, NC). P values < 0.05 were deemed significant.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
All subjects tolerated the study well. Subjects could distinguish the drinks containing gelatin because of their viscous texture.

Blood glucose, plasma insulin, GLP-1, and GIP concentrations
Blood glucose, plasma insulin, GLP-1, and GIP concentrations are shown in Figure 1Go. Blood glucose concentrations increased from baseline after the Glucose and Glucose + Protein drinks (P < 0.05 for each), but not after the Protein drink, and the blood glucose profile differed significantly between the 3 study days (P < 0.005 for both treatment effect and treatment x time interaction). Blood glucose concentrations were lower after the Glucose + Protein drink than after the Glucose drink (P < 0.05), with a lower peak blood glucose value for Glucose + Protein (8.0 ± 0.4 mmol/L) than for Glucose (9.4 ± 0.3 mmol/L) (P < 0.05). For the drinks containing glucose, blood glucose concentrations fell below baseline values late in the study, so that blood glucose was lower for Glucose + Protein than for Protein at 120 and 150 min and was also lower for Glucose than for Protein at 150 min (P < 0.05 for all).


Figure 1
View larger version (29K):
[in this window]
[in a new window]

 
FIGURE 1.. Mean (±SE) concentrations of blood glucose, plasma insulin, plasma glucagon-like peptide 1 (GLP-1), and plasma glucose-dependent insulinotropic polypeptide (GIP) after 50 g oral glucose (Glucose drink; {circ}), 25 g oral protein (Protein drink; {square}), and 50 g oral glucose with 25 g oral protein (Glucose + Protein drink; •). n = 9 subjects. Blood glucose, plasma insulin, and plasma GIP differed significantly between study days (P < 0.005 for all, repeated-measures ANOVA treatment effects and treatment x time interactions), but there was no significant difference in GLP-1 between treatments. Figure 1Significant difference between Glucose + Protein and Glucose drinks, P < 0.05. *Significant difference between Glucose and Protein drinks, P < 0.05. {dagger}Significant difference between Glucose + Protein and Protein drinks, P < 0.05.

 
Plasma insulin concentrations increased from baseline after all 3 drinks (P < 0.005 for treatment effect; P < 0.001 for treatment x time interaction). Insulin concentrations were lower after Protein than after the other drinks (P < 0.05) but did not differ between Glucose and Glucose + Protein. Insulin remained elevated above baseline concentrations after drinks containing glucose, even after blood glucose had returned to, or fallen below, baseline values.

Plasma GLP-1 concentrations increased on all 3 d (P < 0.05), with a relatively early peak followed by a steady decline. There was no significant difference between the 3 drinks.

Plasma GIP concentrations are shown in Figure 1GoD. Plasma GIP increased on all 3 d (P < 0.05 for each), and GIP concentrations differed between study days (P < 0.005 for treatment effect; P < 0.001 for treatment x time interaction). Plasma GIP concentrations were greater after Glucose than after each of the other drinks (P < 0.05 for each) and were greater after Glucose + Protein than after Protein (P < 0.05). As for insulin, GIP remained elevated above baseline beyond the return of blood glucose to baseline.

Gastric emptying
Gastric half-emptying time differed between the 3 study days (P < 0.0005) and was greater for Glucose + Protein (51.2 ± 1.4 min) than for either the Glucose (45.6 ± 1.3 min; P < 0.05) or the Protein (42.1 ± 1.3 min; P < 0.005) drinks (Figure 2Go). Half-emptying time tended to be greater for Glucose than for Protein (P = 0.06). The gastric emptying coefficient tended to differ between the 3 study days (P = 0.05) and on direct comparison was greater for Glucose (3.82 ± 0.07) than for Glucose + Protein (3.61 ± 0.06) (P < 0.05), but it did not differ significantly between Protein (3.98 ± 0.16) and Glucose (P = 0.29) or between Protein and Glucose + Protein (P = 0.07).


Figure 2
View larger version (20K):
[in this window]
[in a new window]

 
FIGURE 2.. Gastric half-emptying time (t1/2) of the 3 drinks. n = 9 subjects. A significant treatment effect was observed (P < 0.0005, ANOVA). Figure 2Significant difference between Glucose + Protein and Glucose drinks, P < 0.05. Significant difference between Glucose and Protein drinks, P = 0.06. {ddagger}Significant difference between Glucose + Protein and Protein drinks, P < 0.005.

 
Relation between blood glucose and gastric emptying
When the Glucose and Glucose + Protein drinks were compared (Figure 3Go), there was an inverse correlation between the change in blood glucose increment at 15 min and the change in gastric half-emptying time (r = –0.77, P < 0.05).


Figure 3
View larger version (15K):
[in this window]
[in a new window]

 
FIGURE 3.. Relation between the change in blood glucose increment at 15 min after the Glucose and Glucose + Protein drinks and the change in gastric half-emptying time (t1/2) between these drinks. n = 9 subjects. An inverse correlation was evident (r = –0.77, P < 0.05).

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The present study is the first to evaluate both gastric emptying and incretin responses to the addition of protein to an oral glucose load in humans. We showed that the addition of protein reduces the glycemic response in healthy subjects and is associated with a slowing of gastric emptying. The latter was predictable given that the stomach empties at a relatively constant caloric rate (11); it is possible that cholecystokinin contributed to this effect, because protein is a potent stimulus for its release (28), although we did not measure plasma cholecystokinin.

Protein did not stimulate additional GLP-1, GIP, or insulin release, and, indeed, plasma GIP concentrations were lower after Glucose + Protein than after the Glucose drink alone. This occurred despite the fact that protein, when consumed alone, stimulated both incretin and insulin release. The increase in plasma insulin after the Protein drink was not associated with any elevation in blood glucose, which suggests that it was mediated by a mechanism other than GLP-1 and GIP, because these peptides stimulate insulin secretion in a glucose-dependent manner (14). A possible alternative mechanism for this effect was the stimulation of ß cells by amino acids (29). The fact that the blood glucose did not decrease in response to the release of insulin could be explained by concurrent glucagon release, although we did not measure this.

The loads of glucose and protein administered in this study were chosen to match those evaluated previously in patients with type 2 diabetes (7). The observed lowering of glycemia after the addition of protein to the glucose drink is in accordance with the report of Gannon et al (7). In contrast with our findings, these authors observed a 2.5-fold stimulation of insulin secretion. However, the insulin response to the glucose drink alone in their type 2 diabetic patients was markedly less than in our healthy subjects. The same investigators then studied the effects of adding glycine (12) or proline (13), both of which are found in gelatin, to oral glucose in healthy volunteers and reported a reduction in blood glucose but no increment in the insulin response. These observations are consistent with the evidence that type 2 diabetes is associated with an impaired early-phase insulin secretion to oral glucose and a diminished glucose-sensing ability of the ß cell, whereas the insulin responses to other stimuli may be relatively intact (30, 31), at least in the early stages of the disease.

Several groups have investigated the insulin response to ingested protein and found that not only the presence of diabetes, but also the relative quantities of protein and carbohydrate and the presence of free amino acids (as opposed to intact protein) are important variables. When ingested in isocaloric quantities, glucose and protein from lean beef have additive effects on insulin secretion in healthy subjects (32), whereas if the amount of protein is less than that of glucose, the increase in insulin is substantially less than additive (33). Furthermore, the insulin response correlates with plasma amino acid concentrations; the insulin response to intact protein is less than that observed with protein hydrolysates, which presumably reflects the more rapid increase in plasma amino acid concentrations with the latter (34).

Little information is available on the effects of supplementing carbohydrate with protein on the incretin response. Frid et al (35) reported that the addition of whey protein to carbohydrate in type 2 diabetic patients increased the insulin response and decreased the glycemic profile more than did the addition of lean ham. The GIP response was greater with whey (area under the curve increased by 30% over 120 min), but GLP-1 concentrations did not significantly differ. Gunnarsson et al (36) recently reported that in gastric gavage-fed mice, the insulin response to glucose (ie, area under the curve) was trebled by the addition of an equal weight of whey protein, and this was associated with a substantial decrease in plasma glucose. The total plasma GLP-1 concentration increased, but GIP did not. However, analysis of intact (or active) incretins indicated an increase in intact GIP, and the authors suggested that fragments of whey protein could inhibit dipeptidyl peptidase IV, the enzyme that degrades the incretin peptides, in the small intestine. As in our study, gastric emptying was slowed by the addition of whey protein to glucose. The fact that the addition of protein in the present study did not increase plasma GLP-1 and decreased GIP is likely to reflect the relatively smaller load and the nature of the protein used. Although we did not measure intact, as opposed to total, GIP, gelatin may be less easily digested to fragments that block dipeptidyl peptidase IV than is whey protein.

We evaluated the acute effects of modest supplementation with protein in healthy individuals. Acute and longer-term studies would be of interest in patients with type 2 diabetes to evaluate the effect of protein supplementation on glycemic control, and the load and type of protein could be optimized for a greater incretin response (34). An alternative approach, eg, the ingestion of a protein "preload" at a given interval before meals, could also be evaluated to determine whether the stimulation of incretins and insulin could improve glycemia after the subsequent meal (37).

In summary, we confirmed the capacity of protein supplementation to improve the glycemic response to glucose in healthy humans, and we showed that the slowing of gastric emptying makes an important contribution to this effect. Further studies aimed at optimizing this phenomenon are indicated in patients with type 2 diabetes, who may derive additional benefit, in terms of postprandial glycemia, from the stimulation of non–glucose-dependent insulin secretion.


    ACKNOWLEDGMENTS
 
The authors' responsibilities were as follows—AK: contributed to the study design, conducted the study, and drafted the manuscript; RC: conducted the study, analyzed the data, and contributed to the writing of the manuscript; SD: contributed to the study design and helped conduct the study; MB: analyzed the breath test data and revised the manuscript; FDB: helped plan the study design with regard to breath testing and reviewed the manuscript; JMW: undertook the peptide assays and analysis of the data; KLJ: contributed to the data analysis and revision of the manuscript; MH: contributed to the conception and design, data analysis, and revision of the manuscript; CKR: conceived the study and oversaw the conduct and analysis of the study and the writing of the manuscript. None of the authors had a conflict of interest to declare.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.[Abstract/Free Full Text]
  2. UK Prospective Diabetes Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837–53.[Medline]
  3. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53.[Abstract/Free Full Text]
  4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17.[Medline]
  5. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090–5.[Abstract/Free Full Text]
  6. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 2003;78:734–41.[Abstract/Free Full Text]
  7. Gannon MC, Nuttall FQ, Neil BJ, Westphal SA. The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects. Metabolism 1988;37:1081–8.[Medline]
  8. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857–62.[Medline]
  9. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001;24:371–81.[Abstract/Free Full Text]
  10. Brener W, Hendrix TR, McHugh PR. Regulation of the gastric emptying of glucose. Gastroenterology 1983;85:76–82.[Medline]
  11. Horowitz M, Dent J, Fraser R, Sun W, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994;39(suppl):7s–13s.[Medline]
  12. Gannon MC, Nuttall JA, Nuttall FQ. The metabolic response to ingested glycine. Am J Clin Nutr 2002;76:1302–7.[Abstract/Free Full Text]
  13. Nuttall FQ, Gannon MC, Jordan K. The metabolic response to ingestion of proline with and without glucose. Metabolism 2004;53:241–6.[Medline]
  14. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199–206.[Abstract/Free Full Text]
  15. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138:159–66.[Abstract/Free Full Text]
  16. Thomas FB, Mazzaferri EL, Crockett SE, Mekhjian HS, Gruemer HD, Cataland S. Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. Gastroenterology 1976;70:523–7.[Medline]
  17. Thomas FB, Sinar D, Mazzaferri EL, et al. Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. Gastroenterology 1978;74:1261–5.[Medline]
  18. Miller LJ, Malagelada JR, Go VL. Intestinal nutrient influence on the enteroinsular axis. J Clin Endocrinol Metab 1978;47:1009–14.[Abstract/Free Full Text]
  19. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117–26.[Medline]
  20. D'Alessio D, Thirlby R, Laschansky E, Zebroski H, Ensinck J. Response of tGLP-1 to nutrients in humans. Digestion 1993;54:377–9.
  21. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717–23.[Abstract/Free Full Text]
  22. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301–7.[Medline]
  23. Horowitz M, Cunningham KM, Wishart JM, Jones KL, Read NW. The effect of short-term dietary supplementation with glucose on gastric emptying of glucose and fructose and oral glucose tolerance in normal subjects. Diabetologia 1996;39:481–6.[Medline]
  24. O'Donovan DG, Doran S, Feinle-Bisset C, et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 2004;89:3431–5.[Abstract/Free Full Text]
  25. Chew CG, Bartholomeusz FD, Bellon M, Chatterton BE. Simultaneous 13C/14C dual isotope breath test measurement of gastric emptying of solid and liquid in normal subjects and patients: comparison with scintigraphy. Nucl Med Rev Cent East Eur 2003;6:29–33.[Medline]
  26. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104:1640–7.[Medline]
  27. Braden B, Adams S, Duan LP, et al. The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology 1995;108:1048–55.[Medline]
  28. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985;75:1144–52.
  29. Fieseler P, Bridenbaugh S, Nustede R, et al. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. Am J Physiol 1995;268:E949–55.[Medline]
  30. Polonsky KS, Sturis J, Bell GI. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777–83.[Free Full Text]
  31. van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, Keizer HA. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care 2003;26:625–30.[Abstract/Free Full Text]
  32. Krezowski PA, Nuttall FQ, Gannon MC, Bartosh NH. The effect of protein ingestion on the metabolic response to oral glucose in normal individuals. Am J Clin Nutr 1986;44:847–56.[Abstract/Free Full Text]
  33. Westphal SA, Gannon MC, Nuttall FQ. Metabolic response to glucose ingested with various amounts of protein. Am J Clin Nutr 1990;52:267–72.[Abstract/Free Full Text]
  34. van Loon LJ, Saris WH, Verhagen H, Wagenmakers AJ. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. Am J Clin Nutr 2000;72:96–105.[Abstract/Free Full Text]
  35. Frid AH, Nilsson M, Holst JJ, Bjorck IM. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 2005;82:69–75.[Abstract/Free Full Text]
  36. Gunnarsson PT, Winzell MS, Deacon CF, et al. Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 2006;147:3173–80.[Abstract/Free Full Text]
  37. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of, and the glycemic, insulin and incretin responses to, a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 2006.
Received for publication July 26, 2007. Accepted for publication July 27, 2007.




This article has been cited by other articles:


Home page
J. Nutr.Home page
R. Hageman, C. Severijnen, B. J. M. van de Heijning, H. Bouritius, N. van Wijk, K. van Laere, and E. M. van der Beek
A Specific Blend of Intact Protein Rich in Aspartate Has Strong Postprandial Glucose Attenuating Properties in Rats
J. Nutr., September 1, 2008; 138(9): 1634 - 1640.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karamanlis, A.
Right arrow Articles by Rayner, C. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karamanlis, A.
Right arrow Articles by Rayner, C. K
Agricola
Right arrow Articles by Karamanlis, A.
Right arrow Articles by Rayner, C. K


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS